Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. We are also developing proprietary Lm-based antigen delivery products for patients suffering from more common cancers. Our lead candidates under development are the oral gamma secretase inhibitor, AL102, for desmoid tumors; ADXS-504, a Lm-based therapy for early-stage prostate cancer, and the intravenous gamma secretase inhibitor, AL101, for adenoid cystic carcinoma. AL102 (RINGSIDE) has received Fast Track Designation from the U.S. FDA and is currently in the Phase 3 segment of a pivotal study for patients with desmoid tumors.
View Top Employees from Ayala Pharmaceuticals| Website | https://www.ayalapharma.com/ |
| Employees | 36 (36 on RocketReach) |
| Founded | 2017 |
| Address | 1313 N Market St, Wilmington, Delaware 19801, US |
| Technologies |
JavaScript,
HTML,
PHP
+34 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Biotechnology, Precision Oncology, Science and Engineering, Targeted Therapy, Pharmaceutical, Drug Development, Health Care, Companion Diagnostics, Biomarkers, Oncology, Rare Diseases |
Looking for a particular Ayala Pharmaceuticals employee's phone or email?
Ayala Pharmaceuticals Questions
David Caron is the Senior Vice President CMC of Ayala Pharmaceuticals.
36 people are employed at Ayala Pharmaceuticals.
Ayala Pharmaceuticals is based in Wilmington, Delaware.
Top Ayala Pharmaceuticals Employees
-
52
-
View
Carmit Nadri-Shay
VP Regulatory Affairs at Ayala Pharmaceuticals
Rehovot, Central District, Israel11
Related Companies
